Homepage - PharmaSignal

Execution Intelligence for Pharma Dealmakers

Understand the structural forces behind pharma deals — from licensing assumptions to post-launch execution drift.

Deal structuring traps
Forecasting failures
Post-close execution drift

PharmaSignal Explainers — How Pharma Deals Really Work

Why Peak-Sales Models Survive Long After Their Credibility Breaks

February 9, 2026

PharmaSignal Explainers

How Local Pricing Autonomy Gets Engineered Out at Deal Sign-Off

By sagarmahajan2886@gmail.comDecember 29, 20250

PharmaSignal Explainers

Why “Approved” Filings Unravel After Central Teams Disengage

By PharmaSignal News DeskDecember 18, 20250

Trending

M&A and Licensing

Novo Nordisk Partners with Vivtex for Oral Biologics

2 Mins Read

M&A and Licensing

Lilly Licenses Monoclonal Antibody from CSL for $100M

3 Mins Read

M&A and Licensing

Madrigal partners with China biotech for RNAi drugs

3 Mins Read

M&A and Licensing

Lilly acquires Orna for $2.4 billion in genetic medicine push

2 Mins Read

Deals in focus

M&A and Licensing

Contingent Value Rights Boost Biotech Deals

M&A and Licensing

Genmab acquires Merus for $8 billion, boosting oncology assets

M&A and Licensing

Oxford Biomedica Engages in Takeover Talks with EQT

M&A and Licensing

Enlaza and Vertex Form $2.4 Billion Collaboration

markets

Market Access

Novo Nordisk’s $199 Ozempic Deal Enhances Telehealth Partnerships

November 21, 2025By PharmaSignal News Desk

Novo Nordisk Ozempic discount at $199 boosts telehealth partnerships, increasing drug access and sales.

Market & Financials

Moderna H5 Influenza Vaccine Secures New Funding

Novo Nordisk Partners with Vivtex for Oral Biologics

Vir and Astellas’ T Cell Engager Shows Promise

Weekly digest

Weekly Digest

PharmaSignal Weekly Brief

PharmaSignal Take This week’s events signal a strong push for strategic alliances and acquisitions, with Lilly’s notable deals…